Premier Gazette recently published an article on the Banyan Hill Publishing editor, Paul Mampilly in the article “Broadening the Tree of Wealth with Paul Mampilly and Banyan Hill Publishing” written by Stephen Ray. The article details the journey Paul Mampilly took from Wall Street to Main Street.
Some #stocks are going to get hit hard because of President Donald #Trump’s trade war threats against #China. Some of these are among the most popular stocks.https://t.co/OqjZlvvst2#NASDAQ #SP500 #Money #Economy #Asset #Investing #Wealth #Commodities #Resources #Trading pic.twitter.com/TRxWXhedSk
— Paul Mampilly (@MampillyGuru) June 28, 2018
Paul Mampilly began his career in finance after studying business administration at Montclair State University. He later received his MBA from the Fordham Gabelli School of Business. After completing his education, he went to work as an assistant portfolio manager at the Bankers Trust Company. Deutsche Bank later bought Bankers Trust where Mampilly became a research assistant. It was this experience that taught him the value of in-depth research into potential stocks and other things that may affect the market. He became a senior research analyst at ING and began to move up the ranks. He became a hedge fund manager where he managed a variety of investments worth many millions of dollars.
Eventually, the investor became one of the leading hedge fund managers in Wall Street when he worked for Kinetics Asset Management. He grew their portfolio to more than $25 billion in assets. Barron’s even named him as one of the “World’s Best” after the portfolio had a 43% return rate.
However, Mampilly quickly became tired of the long hours on Wall Street. He wanted to spend more time with his family which led him to retire at the age of 45. Soon, he began a second career at Banyan Hill Publishing where he began to help the average American learn how to trade. In his newsletter, Profits Unlimited, Mampilly reveals his latest picks in markets like biotech.
In another article, it is revealed that one of Mampilly’s latest picks for his readers is precision medicine. The article titled, “Paul Mampilly Advises His Subscribers to Invest in Precision Medicine” was published on the Dial Dish website. He reveals that precision medicine is the next step in an improved health market where scientists use the biology of patients and pair it with the best possible treatment options. He believes that physicians will be able to use the genomic profile of the patient and compare which treatment will work best.